Cargando…

Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy

BACKGROUND: Sarcomatoid carcinoma is a rare, high-grade malignancy with epithelial and mesenchymal components. It may be a good candidate for immunotherapy because it is associated with overexpression of programmed cell death ligand 1. Sarcomatoid urothelial carcinoma (UC) of the upper urinary tract...

Descripción completa

Detalles Bibliográficos
Autores principales: Anraku, Tsutomu, Hashidate, Hideki, Nakahara, Asa, Imai, Tomoyuki, Kawakami, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024438/
https://www.ncbi.nlm.nih.gov/pubmed/36934227
http://dx.doi.org/10.1186/s12894-023-01210-z
_version_ 1784909101034110976
author Anraku, Tsutomu
Hashidate, Hideki
Nakahara, Asa
Imai, Tomoyuki
Kawakami, Yoshiaki
author_facet Anraku, Tsutomu
Hashidate, Hideki
Nakahara, Asa
Imai, Tomoyuki
Kawakami, Yoshiaki
author_sort Anraku, Tsutomu
collection PubMed
description BACKGROUND: Sarcomatoid carcinoma is a rare, high-grade malignancy with epithelial and mesenchymal components. It may be a good candidate for immunotherapy because it is associated with overexpression of programmed cell death ligand 1. Sarcomatoid urothelial carcinoma (UC) of the upper urinary tract is extremely rare. Here we report the first case of sarcomatoid UC of the renal pelvis that responded to immunotherapy. CASE PRESENTATION: A 79-year-old man was referred to our hospital complaining of various symptoms, including anorexia and abdominal pain. A computed tomography scan revealed a right atrial tumor, a 9 cm left renal mass with a renal vein tumor thrombus, para-aortic lymphadenopathy, and multiple small lung nodules. The patient underwent resection of the right atrial tumor. Pathological analysis of the tumor did not lead to an accurate diagnosis even after several rounds of immunohistochemistry. He underwent a needle biopsy of the left kidney and was initially diagnosed with collecting duct carcinoma, a rare subtype of renal cell carcinoma (RCC). Following the initial diagnosis, immunotherapy with nivolumab and ipilimumab commenced. Thereafter, almost all lesions, including the left renal tumor, were reduced in size. However, he underwent a left nephrectomy approximately a year after beginning immunotherapy due to repeated left renal bleeding. Histological examination of the nephrectomy specimen revealed two forms of cancer—sarcomatoid UC and conventional high-grade UC. Two months after surgery, the patient was found to have new lung metastases. He underwent chemotherapy with gemcitabine and cisplatin, followed by immunotherapy with pembrolizumab. However, both treatments were ineffective. The patient died of cancer 19 months after his first admission. CONCLUSIONS: The presented case of sarcomatoid UC of the renal pelvis that partially responded to immunotherapy suggests that immunotherapy can be a promising treatment for sarcomatoid UC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01210-z.
format Online
Article
Text
id pubmed-10024438
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100244382023-03-19 Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy Anraku, Tsutomu Hashidate, Hideki Nakahara, Asa Imai, Tomoyuki Kawakami, Yoshiaki BMC Urol Case Report BACKGROUND: Sarcomatoid carcinoma is a rare, high-grade malignancy with epithelial and mesenchymal components. It may be a good candidate for immunotherapy because it is associated with overexpression of programmed cell death ligand 1. Sarcomatoid urothelial carcinoma (UC) of the upper urinary tract is extremely rare. Here we report the first case of sarcomatoid UC of the renal pelvis that responded to immunotherapy. CASE PRESENTATION: A 79-year-old man was referred to our hospital complaining of various symptoms, including anorexia and abdominal pain. A computed tomography scan revealed a right atrial tumor, a 9 cm left renal mass with a renal vein tumor thrombus, para-aortic lymphadenopathy, and multiple small lung nodules. The patient underwent resection of the right atrial tumor. Pathological analysis of the tumor did not lead to an accurate diagnosis even after several rounds of immunohistochemistry. He underwent a needle biopsy of the left kidney and was initially diagnosed with collecting duct carcinoma, a rare subtype of renal cell carcinoma (RCC). Following the initial diagnosis, immunotherapy with nivolumab and ipilimumab commenced. Thereafter, almost all lesions, including the left renal tumor, were reduced in size. However, he underwent a left nephrectomy approximately a year after beginning immunotherapy due to repeated left renal bleeding. Histological examination of the nephrectomy specimen revealed two forms of cancer—sarcomatoid UC and conventional high-grade UC. Two months after surgery, the patient was found to have new lung metastases. He underwent chemotherapy with gemcitabine and cisplatin, followed by immunotherapy with pembrolizumab. However, both treatments were ineffective. The patient died of cancer 19 months after his first admission. CONCLUSIONS: The presented case of sarcomatoid UC of the renal pelvis that partially responded to immunotherapy suggests that immunotherapy can be a promising treatment for sarcomatoid UC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12894-023-01210-z. BioMed Central 2023-03-18 /pmc/articles/PMC10024438/ /pubmed/36934227 http://dx.doi.org/10.1186/s12894-023-01210-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Anraku, Tsutomu
Hashidate, Hideki
Nakahara, Asa
Imai, Tomoyuki
Kawakami, Yoshiaki
Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
title Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
title_full Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
title_fullStr Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
title_full_unstemmed Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
title_short Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
title_sort sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024438/
https://www.ncbi.nlm.nih.gov/pubmed/36934227
http://dx.doi.org/10.1186/s12894-023-01210-z
work_keys_str_mv AT anrakutsutomu sarcomatoidurothelialcarcinomaoftherenalpelvistreatedwithimmunotherapy
AT hashidatehideki sarcomatoidurothelialcarcinomaoftherenalpelvistreatedwithimmunotherapy
AT nakaharaasa sarcomatoidurothelialcarcinomaoftherenalpelvistreatedwithimmunotherapy
AT imaitomoyuki sarcomatoidurothelialcarcinomaoftherenalpelvistreatedwithimmunotherapy
AT kawakamiyoshiaki sarcomatoidurothelialcarcinomaoftherenalpelvistreatedwithimmunotherapy